--- title: "BioArctic Q1 operating profit drops to SEK 210.8 million; net revenues fall to SEK 437.6 million" type: "News" locale: "en" url: "https://longbridge.com/en/news/287007818.md" description: "BioArctic reported a Q1 operating profit of SEK 210.8 million, down from SEK 1.08 billion a year prior. Net revenues fell to SEK 437.6 million from SEK 1.29 billion. Cash flow from operations turned negative at SEK 166 million, while cash and equivalents rose to SEK 2.03 billion. Leqembi sales surpassed EUR 500 million, triggering a EUR 20 million milestone. The FDA extended the review of Leqembi treatment by three months, with a new PDUFA date of Aug. 24, 2026." datetime: "2026-05-20T05:05:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287007818.md) - [en](https://longbridge.com/en/news/287007818.md) - [zh-HK](https://longbridge.com/zh-HK/news/287007818.md) --- # BioArctic Q1 operating profit drops to SEK 210.8 million; net revenues fall to SEK 437.6 million - BioArctic posted operating profit of SEK 210.8 million for January–March 2026, down from SEK 1.08 billion a year earlier, while profit for the period fell to SEK 212.4 million from SEK 1.02 billion. \* Net revenues dropped to SEK 437.6 million from SEK 1.29 billion, including SEK 160.8 million in Leqembi royalties and SEK 218.8 million from an Eisai milestone payment. \* Cash flow from operating activities widened to an outflow of SEK 166 million from an inflow of SEK 11.8 million, while cash and cash equivalents including short-term investments rose to SEK 2.03 billion from SEK 788.6 million. \* Leqembi sales exceeded EUR 500 million in Eisai’s financial year 2025, triggering a EUR 20 million milestone; Eisai forecast Leqembi sales of JPY 143.5 billion for fiscal 2026, up 63% year on year. \* The FDA extended the review of Leqembi Iqlik subcutaneous initiation treatment by three months, setting a new PDUFA date of Aug. 24, 2026, while BioArctic said it expects the positive financial development to continue. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here ### Related Stocks - [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [4523.JP](https://longbridge.com/en/quote/4523.JP.md) ## Related News & Research - [Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. | B Stock News](https://longbridge.com/en/news/285676025.md) - [Biogen to advance experimental Alzheimer’s drug despite mid-stage trial miss](https://longbridge.com/en/news/286407083.md) - [TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)](https://longbridge.com/en/news/286442023.md) - [BUZZ-Street View: Skeptical on experimental Alzheimer's drug, awaits full data](https://longbridge.com/en/news/286558948.md) - [Biogen Finalizes Apellis CVR Terms (Up To $4) And Secures $2 Billion Term Loan Facilities](https://longbridge.com/en/news/286417500.md)